Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
暂无分享,去创建一个
G. Petsko | E. Bézard | M. Vila | W. Meissner | C. Olanow | M. Bourdenx | B. Dehay | S. Przedborski | S. Hunot | A. Singleton | P. Gorry | Kalpana M. Merchant
[1] R. Postuma,et al. Parkinson risk in idiopathic REM sleep behavior disorder , 2015, Neurology.
[2] G. Wenning,et al. Multiple-system atrophy. , 2015, The New England journal of medicine.
[3] A. Recasens,et al. Alpha-synuclein spreading in Parkinson’s disease , 2014, Front. Neuroanat..
[4] A. Paetau,et al. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology , 2014, Neurobiology of Aging.
[5] E. Bézard,et al. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives , 2014, The Lancet.
[6] C. Richie,et al. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse , 2014, Neurobiology of Disease.
[7] E. Masliah,et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. , 2014, Human molecular genetics.
[8] Thomas G. Beach,et al. Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry , 2014, Scientific Reports.
[9] E. Bézard,et al. Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies , 2014, Neurobiology of Disease.
[10] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[11] J. Trojanowski,et al. α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration , 2014, Cell reports.
[12] R. Barker,et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.
[13] K. Bötzel,et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset , 2014, Acta Neuropathologica.
[14] Ye Han,et al. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects , 2014, Brain Research.
[15] E. Bézard,et al. Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys , 2014, Annals of neurology.
[16] E. Masliah,et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials , 2014, Acta Neuropathologica.
[17] B. Giasson,et al. Evidence of Native α-Synuclein Conformers in the Human Brain* , 2014, The Journal of Biological Chemistry.
[18] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[19] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[20] E. Schon,et al. α-Synuclein Is Localized to Mitochondria-Associated ER Membranes , 2014, The Journal of Neuroscience.
[21] B. Meier,et al. Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.
[22] R. Edwards,et al. The Function of α-Synuclein , 2013, Neuron.
[23] P. Aebischer,et al. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo , 2013, Proceedings of the National Academy of Sciences.
[24] M. Colombo,et al. Autophagic clearance of bacterial pathogens: molecular recognition of intracellular microorganisms , 2013, Front. Cell. Infect. Microbiol..
[25] Maria Xilouri,et al. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. , 2013, Brain : a journal of neurology.
[26] C. Hetz,et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons , 2013, Autophagy.
[27] M. Farrer,et al. Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[28] A. Rana,et al. Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis , 2013, PloS one.
[29] Anders Björklund,et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity , 2013, Proceedings of the National Academy of Sciences.
[30] P. Tavan,et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease , 2013, Acta Neuropathologica.
[31] Ronald Melki,et al. G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome , 2013, Annals of neurology.
[32] K. Brunden,et al. Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy*♦ , 2013, The Journal of Biological Chemistry.
[33] Christos Proukakis,et al. A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.
[34] E. Masliah,et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.
[35] Nam Ki Lee,et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking , 2013, Proceedings of the National Academy of Sciences.
[36] E. Bézard,et al. Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies , 2013, Movement disorders : official journal of the Movement Disorder Society.
[37] H. Braak,et al. 100 years of Lewy pathology , 2013, Nature Reviews Neurology.
[38] E. Masliah,et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.
[39] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[40] E. Masliah,et al. Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.
[41] V. Baekelandt,et al. A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease , 2012, British journal of pharmacology.
[42] Christopher M. Dobson,et al. Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.
[43] M. Ivanova,et al. A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo , 2012, Neurotherapeutics.
[44] Bernard Schneider,et al. α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.
[45] Jean-Christophe Rochet,et al. Molecular insights into Parkinson's disease. , 2012, Progress in molecular biology and translational science.
[46] S. Koyama,et al. Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease , 2011, The Journal of Neuroscience.
[47] Wei Wang,et al. A soluble α-synuclein construct forms a dynamic tetramer , 2011, Proceedings of the National Academy of Sciences.
[48] B. Hyman,et al. Distinct Roles In Vivo for the Ubiquitin–Proteasome System and the Autophagy–Lysosomal Pathway in the Degradation of α-Synuclein , 2011, The Journal of Neuroscience.
[49] J. Trojanowski,et al. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. , 2011, Cold Spring Harbor perspectives in medicine.
[50] D. Selkoe,et al. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.
[51] Marta Martínez-Vicente,et al. Fighting neurodegeneration with rapamycin: mechanistic insights , 2011, Nature Reviews Neuroscience.
[52] J. Trojanowski,et al. α-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies , 2011, The Journal of Neuroscience.
[53] K. Bankiewicz,et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons , 2011, Brain Research.
[54] E. Masliah,et al. Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model , 2011, The Journal of Neuroscience.
[55] Paola Piccini,et al. Priorities in Parkinson's disease research , 2011, Nature Reviews Drug Discovery.
[56] E. Masliah,et al. Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.
[57] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[58] M. Spillantini,et al. Induction of the unfolded protein response by α‐synuclein in experimental models of Parkinson’s disease , 2011, Journal of neurochemistry.
[59] V. Subramaniam,et al. Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism , 2010, PloS one.
[60] J. Jankovic,et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial , 2010, The Lancet Neurology.
[61] Steve D. M. Brown,et al. α-Synuclein impairs macroautophagy: implications for Parkinson’s disease , 2010, The Journal of cell biology.
[62] M. Vila,et al. Pathogenic Lysosomal Depletion in Parkinson's Disease , 2010, The Journal of Neuroscience.
[63] A. Cuervo,et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation , 2010, Neurobiology of Disease.
[64] J. Henderson,et al. α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra , 2010, PloS one.
[65] Fabia Febbraro,et al. Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology , 2010, The European journal of neuroscience.
[66] R. Mandel,et al. In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[67] Min Jae Lee,et al. Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.
[68] R. Krüger,et al. First appraisal of brain pathology owing to A30P mutant alpha‐synuclein , 2010, Annals of neurology.
[69] D. Ehrnhoefer,et al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.
[70] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[71] Lloyd A Greene,et al. Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.
[72] E. Masliah,et al. Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases , 2009, The Journal of Neuroscience.
[73] H. Jäckle,et al. Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models , 2009, The EMBO journal.
[74] C. Warren Olanow,et al. Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.
[75] S. Przedborski,et al. Intrabody and Parkinson's disease. , 2009, Biochimica et biophysica acta.
[76] David Park,et al. Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy , 2009, PloS one.
[77] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[78] E. Hirsch,et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.
[79] S. Lindquist,et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. , 2008, The Journal of clinical investigation.
[80] P. Lansbury,et al. Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.
[81] D. Berg,et al. Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[83] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[84] Alain Dagher,et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years , 2008, Nature Medicine.
[85] J. Jankovic. Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[86] Peter T Lansbury,et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.
[87] H. Gendelman,et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.
[88] Armin Giese,et al. Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.
[89] M. Feany,et al. Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.
[90] D. Rubinsztein,et al. Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.
[91] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[92] M. Mattson,et al. Ageing and neuronal vulnerability , 2006, Nature Reviews Neuroscience.
[93] Hai Lin,et al. Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[94] M. Feany,et al. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.
[95] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[96] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[97] Jochen Klucken,et al. Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.
[98] Alexxai V. Kravitz,et al. Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation , 2004, Experimental Neurology.
[99] Takeshi Iwatsubo,et al. Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective* , 2004, Journal of Biological Chemistry.
[100] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[101] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[102] B. Giasson,et al. Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.
[103] Jeremy N. Skepper,et al. α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.
[104] E. Bézard. Neuroprotection for Parkinson's disease: a call for clinically riven experimental design , 2003, The Lancet Neurology.
[105] V. Uversky,et al. Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .
[106] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[107] P. Auluck,et al. Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.
[108] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[109] E. Masliah,et al. α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.
[110] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[111] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[112] J Q Trojanowski,et al. A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.
[113] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[114] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[115] L. Meijer,et al. Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.
[116] T. Chase,et al. Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.
[117] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[118] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[119] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[120] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[121] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[122] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[123] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.